Given GLP-1 receptor agonists' established effects on weight, Poizeau and colleagues investigated whether the blockbuster ...

"The absence of a statistically significant benefit of adjuvant chemotherapy in the ASTER 70s trial underlines the persistent ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

Novartis, a New Jersey drug manufacturer, filed the lawsuit in federal court in Portland over the program that allows hospitals and community health centers to get some medications at discount prices.

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

President Donald Trump has called on 17 pharmaceutical companies to implement most-favored-nation drug pricing in the next 60 days.

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, ...

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune ...

Novartis Pharmaceuticals filed a lawsuit against the State of Rhode Island seeking to block the enforcement of a new state ...

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate ...